Patent US5753230A successfully refreshed from Google Patents.
US5753230A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions useful for inhibition of angiogenesis
Assignee: Scripps Research Institute
•
Filing: 1994-03-18
•
Granted: 1998-05-19
•
Expires: 2014-03-18
Abstract
Abstract The present invention describes methods for inhibition of angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing anti-α v β 3 monoclonal antibodies.
Inventors
- 👤 Peter Brooks
- 👤 David A. Cheresh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 01:51
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/78; A; A61; A61K; A61K39/00; A61K39/395; A61P; A61P19/00; A61P19/02; A61P27/00; A61P27/02; A61P29/00; A61P3/00; A61P3/08; A61P3/10; A61P35/00; A61P35/04; A61P43/00; A61P9/00; A61P9/08; A61P9/10; A61P9/14; C07K14/705; C07K14/70546; C07K14/70557; C07K16/00; C07K16/18; C07K16/28; C07K16/2839; C07K16/2848; C07K16/30; A61K2039/505; A61K38/00
Claims Analysis
Total Claims: 44
Claim 1
Independent Claim
86 words
A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin α v β 3 detectable by immunohistochemistry comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-α v β 3 monoclonal antibody, whereby integrin α v β 3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.
Claim 2
Independent Claim
86 words
A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin α v β 3 detectable by immunohistochemistry comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-α v β 3 monoclonal antibody, whereby integrin α v β 3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.
Claim 3
Dependent Claim
37 words
The method of claim 1 wherein said anti-α v β 3 antibody inhibits binding of fibrinogen to integrin α v β 3 but does not substantially inhibit binding of fibrinogen to integrin α IIb β 3 .
Claim 4
Dependent Claim
22 words
The method of claim 1 wherein said monoclonal antibody has the immunoreaction characteristics of monoclonal antibody LM609having ATCC accession number HB 9537.
Claim 5
Dependent Claim
18 words
The method of claim 1 wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.
Claim 6
Dependent Claim
11 words
The method of claim 1 wherein said administering comprises intravenous administration.
Claim 7
Dependent Claim
11 words
The method of claim 1 wherein said administering comprises intrasynovial administration.
Claim 8
Dependent Claim
11 words
The method of claim 1 wherein said administering comprises transdermal administration.
Claim 9
Dependent Claim
11 words
The method of claim 1 wherein said administering comprises intramuscular administration.
Claim 10
Dependent Claim
11 words
The method of claim 1 wherein said administering comprises oral administration.
Claim 11
Dependent Claim
14 words
The methods of claim 1 wherein said administering is conducted in conjunction with chemotherapy.
Claim 12
Dependent Claim
10 words
The method of claim 1 wherein the patient is human.
Claim 13
Dependent Claim
10 words
The method of claim 11 wherein the antibody is humanized.
Claim 14
Dependent Claim
23 words
The method of claim 12 wherein the humanized antibody has the immunoreaction characteristics of monoclonal antibody LM609 having ATCC accession number HB 9537.
Claim 15
Dependent Claim
20 words
The method of claim 1 wherein the anti-α v β 3 antibody specifically binds integrin α v β 3 complex.
Claim 16
Dependent Claim
10 words
The method of claim 1 wherein the tumor is metastasized.
Claim 17
Independent Claim
94 words
A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin α v β 3 detectable by immunohistochemistry with monoclonal antibody LM609 having ATCC accession number HB9537, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of anti-α v β 3 monoclonal antibody, whereby integrin α v β 3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.
Claim 18
Independent Claim
94 words
A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin α v β 3 detectable by immunohistochemistry with monoclonal antibody LM609 having ATCC accession number HB9537, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of anti-α v β 3 monoclonal antibody, whereby integrin α v β 3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.
Claim 19
Dependent Claim
26 words
The method of claim 16 wherein said anti-α v β 3 monoclonal antibody has the immunoreaction characteristics of monoclonal antibody LM609 having ATCC accession number HB9537.
Claim 20
Dependent Claim
10 words
The method of claim 16 wherein said patient is human.
Claim 21
Dependent Claim
15 words
The method of claim 18 wherein said anti-α v β 3 monoclonal antibody is humanized.
Claim 22
Dependent Claim
23 words
The method of claim 19 wherein the humanized antibody has the immunoreaction characteristics of monoclonal antibody LM609 having ATCC accession number HB 9537.
Claim 23
Dependent Claim
20 words
The method of claim 16 wherein the anti-α v β 3 antibody specifically binds integrin α v β 3 complex.
Claim 24
Dependent Claim
11 words
The method of claim 16 wherein said administering comprises intravenous administration.
Claim 25
Dependent Claim
11 words
The method of claim 16 wherein said administering comprises intrasynovial administration.
Claim 26
Dependent Claim
11 words
The method of claim 16 wherein said administering comprises transdermal administration.
Claim 27
Dependent Claim
11 words
The method of claim 16 wherein said administering comprises intramuscular administration.
Claim 28
Dependent Claim
11 words
The method of claim 16 wherein said administering comprises oral administration.
Claim 29
Independent Claim
70 words
A method for inhibiting angiogenesis in an inflamed, angiogenic tissue of a patient, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-α v β 3 monoclonal antibody, whereby integrin α v β 3 expressed on the surface of vascular endothelial cells involved in said angiogenesis in said angiogenic tissue is contacted by said antibody resulting in inhibition in the blood supply to said angiogenic tissue.
Claim 30
Independent Claim
70 words
A method for inhibiting angiogenesis in an inflamed, angiogenic tissue of a patient, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-α v β 3 monoclonal antibody, whereby integrin α v β 3 expressed on the surface of vascular endothelial cells involved in said angiogenesis in said angiogenic tissue is contacted by said antibody resulting in inhibition in the blood supply to said angiogenic tissue.
Claim 31
Dependent Claim
23 words
The method of claim 27 wherein said monoclonal antibody has the immunoreaction characteristics of monoclonal antibody LM609 having ATCC accession number HB 9537.
Claim 32
Dependent Claim
10 words
The method of claim 27 wherein said patient is human.
Claim 33
Dependent Claim
10 words
The method of claim 29 wherein said antibody is humanized.
Claim 34
Dependent Claim
23 words
The method of claim 30 wherein the humanized antibody has the immunoreaction characteristics of monoclonal antibody LM609 having ATCC accession number HB 9537.
Claim 35
Dependent Claim
20 words
The method of claim 27 wherein the anti-α v β 3 antibody specifically binds integrin α v β 3 complex.
Claim 36
Dependent Claim
10 words
The method of claim 27 wherein said tissue is arthritic.
Claim 37
Dependent Claim
17 words
The method of claim 33 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.
Claim 38
Dependent Claim
24 words
The method of claim 27 wherein said tissue is the retinal tissue of a patient with diabetic retinopathy and said angiogenesis is retinal angiogenesis.
Claim 39
Dependent Claim
11 words
The method of claim 27 wherein said administering comprises intravenous administration.
Claim 40
Dependent Claim
11 words
The method of claim 27 wherein said administering comprises intrasynovial administration.
Claim 41
Dependent Claim
11 words
The method of claim 27 wherein said administering comprises transdermal administration.
Claim 42
Dependent Claim
11 words
The method of claim 27 wherein said administering comprises intramuscular administration.
Claim 43
Dependent Claim
11 words
The method of claim 27 wherein said administering comprises oral administration.
Claim 44
Dependent Claim
16 words
The method of claim 27 wherein the tissue is retinal tissue the angiogenesis is retinal angiogenesis.
References Cited (Backward Citations)
US5092885A
Cited
WO1989005155A1
Cited
US5112946A
Cited
US5262520A
Cited
US5192744A
Cited
US5202352A
Cited
EP0576898A2
Cited
EP0578083A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-05-18 | 2001-11-17 | 2002-05-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-05-18 | 2005-11-17 | 2006-05-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-05-18 | 2009-11-17 | 2010-05-19 | $7700.00 | Window Closed / Lapsed |